Woodcock’s Passion Project: CDER Chief Shifts Duties To Lead Quality Office
Executive Summary
Deputies are taking on some of Woodcock’s usual responsibilities to allow the center director more time to oversee launch of new Office of Pharmaceutical Quality.
You may also be interested in...
US FDA’s Regulatory Affairs Office Building Case For More User Fee Funding
ORA represented only a small fraction of the user fee programs’ costs in recent years, but wants to show its importance to the review process.
Gottlieb Promotes 'Team' Work For Product Reviews
US FDA Commissioner intends to change agency's siloed structure and move reviewers into teams that will follow products pre- and post-market.
'Brilliant' and 'Steady' Jenkins Retiring From US FDA's Office of New Drugs
Implementer of many drug review changes will leave in January after nearly 32 years of public service.